Download Files:
JND3229
$310 – $2,400
Products Details
Product Description
– JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1].
Web ID
– HY-119944
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C33H41ClN8O2
References
– [1]Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127.
CAS Number
– 2260886-64-2
Molecular Weight
– 617.18
Compound Purity
– 99.78
SMILES
– CC1=CC(NC2=NC(N([C@@H]3CC[C@@H](NC(CC)=O)CC3)C(N(C4=C(Cl)C=CC=C4)C5)=O)=C5C=N2)=CC=C1N6CCN(C)CC6
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 12.5 mg/mL (ultrasonic)
Target
– EGFR
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
